OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Clinical Pharmacology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Issue Highlights	84
	82
Issue Information	71
	71
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	60
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	58
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	58
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	52
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	51
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐	51
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	49
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	47
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	45
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	45
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	45
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	45
Lemborexant levels in breast milk after single doses in healthy, lactating women	41
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	40
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	39
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	37
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	37
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	36
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	35
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	35
Modelling the progression of illicit substance use patterns from real‐world evidence	33

Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	33
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	32
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	32
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	32
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	32
Selected Abstracts from Pharmacology 2024	32
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	31